Clinical trials: Envafolimab
Advanced Solid Tumor
Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program
Envafolimab is a novel PD-L1 inhibitor administered via subcutaneous (SC) injection - notably the first such checkpoint inhibitor approved for use worldwide.[1] In November 2021, Envafolimab received its first approval in China…
- Trial name
- ENCOMPASS STUD (NCT07562347)
- Testing
- Envafolimab
- Volunteers
- 120 people
- Sponsor
- IR INNOVATE RESEARCH PRIVATE LIMITED
Non-small Cell Lung Cancer
A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC
The objective of this prospective, single-arm, single-center clinical study is to evaluate the efficacy and safety of envafolimab combined with platinum-containing dual-drug chemotherapy and recombinant human endostatin regimens…
- Trial name
- NCT05360979
- Testing
- envafolimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Xiangya Hospital of Central South University
Rectal Cancer
Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma
Short-course radiotherapy combined with immunotherapy may bring revolutionary changes to the total neoadjuvant therapy mode for locally advanced ultra low rectal cancer to preserve the organs.
- Trial name
- RECMULRA-TNT (NCT05858567)
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
Ovarian Cancer, Epithelial
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT05422183
- Testing
- Envafolimab, Lenvatinib, VP-16
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhongda Hospital
Non-small Cell Lung Cancer
Local Injection and Systemic Therapy in the Treatment of NSCLC.
This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection…
- Trial name
- NCT06618391
- Testing
- Envafolimab, Recombinant human endostatin, recombinant human adenovirus type 5
- Volunteers
- 84 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Envafolimab injection (PD-L1) combined with Disitamab Vedotin (HER2 ADC) and Carboplatin for resectable, HER2-Mutant…
- Trial name
- neovision (NCT06734182)
- Testing
- Envafolimab injections+intravenous Disitamab Vedotin+carboplatin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Guangdong Provincial People's Hospital
Biliary Tract Cancer
Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies
This trial is to evaluate the efficacy of Gemcitabine-Cisplatin (GC) plus Envafolimab neoadjuvant therapy in the patients at high risk of recurrence. Primary endpoint: Major Pathologic Response (MPR).
- Trial name
- GENE (NCT07599995)
- Testing
- Neoadjuvant therapy followed by surgery
- Volunteers
- 34 people
- Sponsor
- Sir Run Run Shaw Hospital
Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Preoperative radiotherapy combined with 5-fluorouracil/capecitabine is currently the standard treatment for locally advanced rectal cancer.
- Trial name
- ESTIMATE (NCT06239870)
- Testing
- Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yunnan Cancer Hospital
Locally Advanced Rectal Carcinoma, MSI-High
Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
This is a single center, prospective, single arm clinical trial to evaluate the efficacy and safety of Envafolimab as a neoadjuvant therapy for resectable and locally advanced dMMR or MSI-H rectal cancer.
- Trial name
- NCT05645094
- Testing
- Envafolimab
- Volunteers
- 38 people
- Sponsor
- Fudan University
Metastatic Gastrointestinal Stromal Tumors (GIST)
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
This study is a multicenter, prospective, randomized controlled Phase II clinical trial. The primary endpoint is to evaluate the efficacy and safety of regorafenib combined with envafolimab compared to physician's choice in…
- Trial name
- NCT06772233
- Testing
- regorafenib combined with envafolimab, Control Group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University
Potentially Resectable Hepatocellular Carcinoma
Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion
This study is a single-center, exploratory clinical trial. Eligible patients with liver cancer, after signing the informed consent form, will be screened and enrolled.
- Trial name
- HCC (NCT07738055)
- Testing
- Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeks
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Neoplasms
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression
- Trial name
- NCT05203276
- Testing
- Envafolimab, Endostar
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Biliary Tract Cancer
Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer
Advanced biliary tract cancer has a poor prognosis and limited efficacy with current regimens. This multicenter single-arm phase Ib/II trial explores the efficacy and safety of HAI-GP chemotherapy combined with intraoperative…
- Trial name
- NCT07636798
- Testing
- HAIC Combined Regimen Treatment Group
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Biliary Tract Cancer, Advanced Cancer
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Brief Summary The goal of this clinical trial is to test whether the combination of Envafolimab (an immunotherapy drug), chemotherapy (gemcitabine + cisplatin), and simvastatin can help treat advanced biliary tract cancer (BTC)…
- Trial name
- NCT07003815
- Testing
- Envafolimab + Gemcitabine + Cisplatin + Simvastatin
- Volunteers
- 62 people
- Sponsor
- Tongji Hospital
Gastrointestinal Neoplasms
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
This is a single-arm, prospective, exploratory clinical study to evaluate the efficacy and safety of endostar combined with stereotactic body radiation therapy (SBRT) and Envafolimab in patients with advanced gastrointestinal…
- Trial name
- NCT06301828
- Testing
- Envafolimab Injection, Endostar
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
RAS Mutation, Metastatic Colorectal Cancer
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to…
- Conditions
- RAS Mutation, Metastatic Colorectal Cancer, MSS
- Trial name
- NCT06321081
- Testing
- irinotecan, cetuximab, envafolimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Hospital
Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
In this study, we investigated the efficacy and safty of surufatinib combined with envafolimab followed by surufatinib as second or more - line therapy in advanced soft tissue sarcoma patients.
- Trial name
- NCT05722977
- Testing
- Surufatinib + envafolimab
- Volunteers
- 45 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Mucosal Melanoma
Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma
This is a phase II, open, single-center study to explore the efficacy and safety of Envafolimab combined with recombinant human endostatin, temozolomide and cisplatin in the treatment of mucosal melanin.
- Trial name
- NCT06041724
- Testing
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- Volunteers
- 46 people
- Sponsor
- Fudan University
Metastatic or Recurrent Gastric Adenocarcinoma
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
The objective is to investigate the efficacy and safety of Envafolimab combined with chemotherapy in the treatment of metastatic or recurrent gastric adenocarcinoma.
- Trial name
- NCT05237349
- Testing
- Envafolimab, Oxaliplatin, S1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Liangjun Zhu M.M.
Advanced Hepatocellular Carcinoma
Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
This study is a single-center, open, single-arm, phase II clinical trial. Eligible HCC patients, after signing informed consent, will receive TACE treatment.
- Trial name
- CISLD-12 (NCT05213221)
- Testing
- Envafolimab, TACE, Lenvatinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Zhejiang University